NCT07088341

Brief Summary

  1. 1.\- Evaluation of diagnostic importance of soluble programmed death ligand-1 in patient with recently diagnosed as Colorectal cancer at different stages of disease .
  2. 2.Correlation of SPDL-1 level and clinco-pathological data of patients at presentation .

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
4mo left

Started Aug 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress71%
Aug 2025Sep 2026

First Submitted

Initial submission to the registry

July 19, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 28, 2025

Completed
4 days until next milestone

Study Start

First participant enrolled

August 1, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2026

Expected
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

July 28, 2025

Status Verified

July 1, 2025

Enrollment Period

1.1 years

First QC Date

July 19, 2025

Last Update Submit

July 19, 2025

Conditions

Colo-rectal Cancer

Outcome Measures

Primary Outcomes (1)

  • Study the expression level of sPDL 1 in colorectal cancer by ELISA

    Correlate the expression level of sPDL-1 and stage of disease

    baseline

Interventions

elisaDIAGNOSTIC_TEST

enzyme- linked immunesorbent assay ( ELISA ) was used to measure soluble programmed death ligand-1 level

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Cases and controls will be recruited from clinical pathology department at South Egypt Cancer Institute, and Assuit University Hospital

You may qualify if:

  • \. Patients did not undergo colorectal surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Shao W, Xu Y, Lin S, Gao J, Gao J, Wang H. The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer. Front Oncol. 2022 Aug 16;12:988567. doi: 10.3389/fonc.2022.988567. eCollection 2022.

    PMID: 36052227BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum or plasma

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Central Study Contacts

marwa mamdouh mohamed abdellah, residant doctor

CONTACT

01153538300marwaamamdouh26@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident doctor

Study Record Dates

First Submitted

July 19, 2025

First Posted

July 28, 2025

Study Start

August 1, 2025

Primary Completion (Estimated)

August 30, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

July 28, 2025

Record last verified: 2025-07